771 related articles for article (PubMed ID: 29792857)
21. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
[TBL] [Abstract][Full Text] [Related]
22. The role of curcumae rhizoma-sparganii rhizoma medicated serum in epithelial-mesenchymal transition in the triple negative breast cancer: Pharmacological role of CR-SR in the TBNC.
Yin Y; Feng L; Wang L; Ding L
Biomed Pharmacother; 2018 Mar; 99():340-345. PubMed ID: 29358127
[TBL] [Abstract][Full Text] [Related]
23. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
24. Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer.
Ma G; Huang H; Li M; Li L; Kong P; Zhu Y; Xia T; Wang S
Cancer Biomark; 2018; 22(3):405-415. PubMed ID: 29758926
[TBL] [Abstract][Full Text] [Related]
25. Tetrandrine Inhibits Cancer Stem Cell Characteristics and Epithelial to Mesenchymal Transition in Triple-Negative Breast Cancer via SOD1/ROS Signaling Pathway.
Liu T; Li K; Zhang Z; Peng J; Yang J; Law BYK; Liu X; Li W
Am J Chin Med; 2023; 51(2):425-444. PubMed ID: 36692485
[TBL] [Abstract][Full Text] [Related]
26. Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells.
Kashyap A; Umar SM; Dev J R A; Prasad CP
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2177-2184. PubMed ID: 34319041
[TBL] [Abstract][Full Text] [Related]
27. IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling.
Jung SY; Yi JY; Kim MH; Song KH; Kang SM; Ahn J; Hwang SG; Nam KY; Song JY
Oncol Rep; 2015 Nov; 34(5):2731-7. PubMed ID: 26351897
[TBL] [Abstract][Full Text] [Related]
28. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
29. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
30. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
[TBL] [Abstract][Full Text] [Related]
31. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
Shome R; Ghosh SS
Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
[TBL] [Abstract][Full Text] [Related]
32. Hard antler extract inhibits invasion and epithelial-mesenchymal transition of triple-negative and Her-2
Xu G; Zhao H; Xu J; Zhang Y; Qi X; Shi A
J Ethnopharmacol; 2021 Apr; 269():113705. PubMed ID: 33346025
[TBL] [Abstract][Full Text] [Related]
33. RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells.
Lv F; Si W; Xu X; He X; Wang Y; Li Y; Li F
Neoplasia; 2024 Feb; 48():100967. PubMed ID: 38219710
[TBL] [Abstract][Full Text] [Related]
34. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.
So JY; Lin JJ; Wahler J; Liby KT; Sporn MB; Suh N
PLoS One; 2014; 9(9):e107616. PubMed ID: 25229616
[TBL] [Abstract][Full Text] [Related]
35. Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer.
Tian J; Hachim MY; Hachim IY; Dai M; Lo C; Raffa FA; Ali S; Lebrun JJ
Sci Rep; 2017 Jan; 7():40258. PubMed ID: 28054666
[TBL] [Abstract][Full Text] [Related]
36. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model.
Guo Y; Fan Y; Pei X
Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729
[TBL] [Abstract][Full Text] [Related]
37. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
[TBL] [Abstract][Full Text] [Related]
38. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
39. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
Doherty MR; Cheon H; Junk DJ; Vinayak S; Varadan V; Telli ML; Ford JM; Stark GR; Jackson MW
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13792-13797. PubMed ID: 29229854
[TBL] [Abstract][Full Text] [Related]
40. Berberine Suppresses Cell Motility Through Downregulation of TGF-β1 in Triple Negative Breast Cancer Cells.
Kim S; Lee J; You D; Jeong Y; Jeon M; Yu J; Kim SW; Nam SJ; Lee JE
Cell Physiol Biochem; 2018; 45(2):795-807. PubMed ID: 29414799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]